Results of ABMT for AML in CR2
| Institution . | No. of Patients . | Median Age (yr) . | Pretransplant Regimen . | Purge . | Actuarial Incidence of (at months) . | Comment . | Reference . | |
|---|---|---|---|---|---|---|---|---|
| LFS . | Relapse . | |||||||
| Baltimore | 82 | 30 | BU-CY4 | 4 HC | 30 (120) | 58 | 35, 36 | |
| Minneapolis | 31 | CY/FTBI v BU-CY4 | 4HC | 38 v 7 | CY/FTBI better | 23 | ||
| San Francisco + Berkeley | 25 | 35 | BU + VP16 | 4HC | 52 (80) | 35 | CR2 + CR3 | 27, 28 |
| Roma | 60 | 28 | BAVC | No | 42 (120) | 56 | Longer CR1 (>12 mo) favorable | 48 |
| Madrid | 16 | 27 | CY/FTBI BU-CY2 | No | 41.6 (60) | 48.7 | Similar to allo-BMT | 49 |
| Pittsburgh | 29 44 | 38 | CY/FTBI BUCY2 | MoAb CD14 CD15 | 21 (36) 41 (35) | 58 39 | CR2 + CR3 patients BUCY2 better | 33, 34 |
| EBMT | 190 | 34 | All regimens combined | No | 30 | 63 | Similar to allo-BMT | 47 |
| Institution . | No. of Patients . | Median Age (yr) . | Pretransplant Regimen . | Purge . | Actuarial Incidence of (at months) . | Comment . | Reference . | |
|---|---|---|---|---|---|---|---|---|
| LFS . | Relapse . | |||||||
| Baltimore | 82 | 30 | BU-CY4 | 4 HC | 30 (120) | 58 | 35, 36 | |
| Minneapolis | 31 | CY/FTBI v BU-CY4 | 4HC | 38 v 7 | CY/FTBI better | 23 | ||
| San Francisco + Berkeley | 25 | 35 | BU + VP16 | 4HC | 52 (80) | 35 | CR2 + CR3 | 27, 28 |
| Roma | 60 | 28 | BAVC | No | 42 (120) | 56 | Longer CR1 (>12 mo) favorable | 48 |
| Madrid | 16 | 27 | CY/FTBI BU-CY2 | No | 41.6 (60) | 48.7 | Similar to allo-BMT | 49 |
| Pittsburgh | 29 44 | 38 | CY/FTBI BUCY2 | MoAb CD14 CD15 | 21 (36) 41 (35) | 58 39 | CR2 + CR3 patients BUCY2 better | 33, 34 |
| EBMT | 190 | 34 | All regimens combined | No | 30 | 63 | Similar to allo-BMT | 47 |
Abbreviations: 4HC, 4 hydroperoxycyclophosphamide; MoAb, monoclonal antibodies; LFS, leukemia-free survival.